Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Galectin-3 and new-onset CKD: marker or mediator?

Literature DB >> 23787910

Galectin-3 and new-onset CKD: marker or mediator?

Pietro Ravani, Brendan J Barrett.

Abstract

Entities: Gene

Mesh：

Substances：
Galectin 3

Year: 2013 PMID： 23787910 PMCID： PMC3752957 DOI： 10.1681/ASN.2013050552

Source DB: PubMed Journal: J Am Soc Nephrol ISSN： 1046-6673 Impact factor: 10.121

× No keyword cloud information.

21 in total

1. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses.

Authors: John P A Ioannidis; Orestis A Panagiotou
Journal: JAMA Date: 2011-06-01 Impact factor: 56.272

2. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

Authors: J F Mann; H C Gerstein; J Pogue; J Bosch; S Yusuf
Journal: Ann Intern Med Date: 2001-04-17 Impact factor: 25.391

3. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study.

Authors: Marcello Tonelli; Paul Muntner; Anita Lloyd; Braden J Manns; Matthew T James; Scott Klarenbach; Robert R Quinn; Natasha Wiebe; Brenda R Hemmelgarn
Journal: Ann Intern Med Date: 2011-01-04 Impact factor: 25.391

4. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

Authors: W H Wilson Tang; Kevin Shrestha; Zhili Shao; Allen G Borowski; Richard W Troughton; James D Thomas; Allan L Klein
Journal: Am J Cardiol Date: 2011-05-19 Impact factor: 2.778

5. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.

Authors: Jennifer E Ho; Chunyu Liu; Asya Lyass; Paul Courchesne; Michael J Pencina; Ramachandran S Vasan; Martin G Larson; Daniel Levy
Journal: J Am Coll Cardiol Date: 2012-08-29 Impact factor: 24.094

6. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes.

Authors: Johanna Weigert; Markus Neumeier; Josef Wanninger; Sabrina Bauer; Stefan Farkas; Marcus N Scherer; Andreas Schnitzbauer; Andreas Schäffler; Charalampos Aslanidis; Jürgen Schölmerich; Christa Buechler
Journal: J Clin Endocrinol Metab Date: 2010-01-15 Impact factor: 5.958

7. Gene therapy with galectin-3 inhibits bronchial obstruction and inflammation in antigen-challenged rats through interleukin-5 gene downregulation.

Authors: Victoria del Pozo; Marta Rojo; Maria L Rubio; Isabel Cortegano; Blanca Cárdaba; Soledad Gallardo; Mercedes Ortega; Esther Civantos; Esther López; Carmen Martín-Mosquero; Germán Peces-Barba; Pilar Palomino; Nicolas González-Mangado; Carlos Lahoz
Journal: Am J Respir Crit Care Med Date: 2002-09-01 Impact factor: 21.405

Galectin-3 and new-onset CKD: marker or mediator?

1. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses.

2. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.

3. Using proteinuria and estimated glomerular filtration rate to classify risk in patients with chronic kidney disease: a cohort study.

4. Usefulness of plasma galectin-3 levels in systolic heart failure to predict renal insufficiency and survival.

5. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community.

6. Serum galectin-3 is elevated in obesity and negatively correlates with glycosylated hemoglobin in type 2 diabetes.

7. Gene therapy with galectin-3 inhibits bronchial obstruction and inflammation in antigen-challenged rats through interleukin-5 gene downregulation.

8. Elevated galectin-3 precedes the development of CKD.

9. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease.

10. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction.

1. Diagnostic and prognostic value of galectin-3, serum creatinine, and cystatin C in chronic kidney diseases.

2. Soluble ST2 and Galectin-3: What We Know and Don't Know Analytically.